无法破译 发表于 2025-3-23 11:57:42

Submitted on: 17 November 2017.
Revised on: 23 December 2017.
Accepted on: 13 January 2018.
Neurology and Therapy---SPRINGER LONDON LTD

Insatiable 发表于 2025-3-23 16:19:56

Submitted on: 13 August 1999.
Revised on: 26 September 1999.
Accepted on: 09 October 1999.
Neurology and Therapy

FACET 发表于 2025-3-23 19:36:30

Submitted on: 21 October 2008.
Revised on: 21 November 2008.
Accepted on: 13 December 2008.
Neurology and Therapy---SPRINGER LONDON LTD

非实体 发表于 2025-3-24 00:25:27

Submitted on: 06 August 2011.
Revised on: 06 September 2011.
Accepted on: 27 September 2011.
Neurology and Therapy---SPRINGER LONDON LTD

epinephrine 发表于 2025-3-24 04:13:16

http://reply.papertrans.cn/3/230/22947/22947-15.png

忧伤 发表于 2025-3-24 10:32:30

http://reply.papertrans.cn/3/230/22947/22947-16.png

etidronate 发表于 2025-3-24 13:59:58

http://reply.papertrans.cn/3/230/22947/22947-17.png

圆木可阻碍 发表于 2025-3-24 16:17:53

http://reply.papertrans.cn/3/230/22947/22947-18.png

未开化 发表于 2025-3-24 20:49:06

Submitted on: 16 February 2016.
Revised on: 23 March 2016.
Accepted on: 05 April 2016.
Neurology and Therapy---SPRINGER LONDON LTD

Gum-Disease 发表于 2025-3-25 00:54:17

Submitted on: 25 June 2020.
Revised on: 15 July 2020.
Accepted on: 28 July 2020.
Neurology and Therapy
页: 1 [2] 3 4
查看完整版本: SCIE期刊Neurology and Therapy 2024/2025影响因子:3.963 (NEUROL THER) (2193-8253). (CLINICAL NEUROLOGY)(临床神经病学)Science Citation